350 rub
Journal №10 for 2012 г.
Article in number:
The IGF-System as One of the Pathogenetic Factors and Potential Target for Antitumor Therapy or Prostate Cancer
Keywords: IGF IGF receptors IGF binding proteins prostate cancer target antitumour therapy
Authors:
A.A. Morozov, A.P. Morozov, M.F. Trapeznokova
Abstract:
The authors discuss recent 10-years data about mechanisms of realization of IGF-signaling pathway effects on prostate cells. The IGF-signaling pathway is a multicomponent system including IGF, IGF receptors and IGF binding proteins, and acting on cells in endocrine, and also auto/paracrine manner. The data of metaanalysis of clinical significance investigations demonstrate undoubted involving of IGF, IGF-R1 and IGFSB in prostate cancerogenesis and tumour progression, although precise correlations between components of IGF-system and prostate cancer rescue, clinico-morphological features and prognosis in prostate cancer are not established because of complete cross-interactions with other mithogenic and proapoptotic signaling pathways. Different components of IGF-system could be interesting as potential targets of antitumour therapy of prostate cancer: there are more perspective data about antitumour effects of antiIGF-R1 monoclonal antibodies, and of tirosinkinase inhibitors.
Pages: 4-11
References
  1. Pollak M.N., Schernhammer E.S., Hankinson S.E. Insulin-like growth factors and neoplasia // Nat. Rev. Cancer. 2004. V. 4. P. 505-518.
  2. Yakar S., Leroith D., Brodt P. The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: Lessons from animal models // Cytokine Growth Factor Rev. 2005. V. 16. P. 407-420.
  3. Герштейн Е.С., Кушлинский Н.Е. Современные представления о механизмах передачи сигналов факторов роста как основа эффективной молекулярно-направленной противоопухолевой терапии // Вопросы биологической, медицинской и фармацевтической химии. 2007. № 1. С. 4-9.
  4. Frasca F., Pandini G., Sciacca L. et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases // Arch. Physiol. Biochem. 2008. V. 114. № 1. P. 23-37.
  5. Grimberg A.Mechanisms by which IGF-I may promote cancer // Cancer Biol. Ther. 2003. V. 2. № 6. p. 630-635.
  6. Gu F., Schumacher F.R., Canzian F. et al.Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer // Cancer Epidemiol. Biomarkers Prev. 2010. V. 19. № 11. P. 2877-2887.
  7. Samani A.A., Yakar S., LeRoith D. et al. The role of the IGF system in cancer growth and metastasis: overview and recent insights // Endocr. Rev. 2007. V. 28. № 1. P. 20-47.
  8. Belfiore A.The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer // Curr. Pharm. Des. 2007. V. 13. № 7. P. 671-686.
  9. Ghosh P.M., Malik S.N., Bedolla R.G. et al. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation // Endocr. Relat. Cancer. 2005. V. 12. № 1. P. 119-134.
  10. Hartog H., Wesseling J., Boezen H.M. et al. The insulin-like growth factor 1 receptor in cancer: old focus, new future // Eur. J. Cancer. 2007. V. 43. № 13. p. 1895-1904.
  11. Larsson O., Girnita A., Girnita L. Role of insulin-like growth factor 1 receptor signalling in cancer // Br. J. Cancer. 2007. V. 96 (Suppl.). P. 2-6.
  12. Laviola L., Natalicchio A., Giorgino F. The IGF-I signaling pathway // Curr. Pharm. Des. 2007. V. 13. № 7. P. 663-669.
  13. Pavelić J., Matijević T., Knezević J.Biological & physiological aspects of action of insulin-like growth factor peptide family // Indian J. Med. Res. 2007. V. 125. № 4. p. 511-522.
  14. Jogie-Brahim Sh., Feldman D., and Oh Y. Unraveling Insulin-Like Growth Factor Binding Protein-3 Actions in Human Disease // Endocr. Rev. 2009. V. 30. № 5. P. 417-437.
  15. Meinbach D.S., Lokeshwar B.L.Insulin-like growth factors and their binding proteins in prostate cancer: cause or consequence - // Urol. Oncol. 2006. V. 24. № 4. P. 294-306.
  16. Li R., Pourpak A., Morris S.W. Inhibition of the Insulin-like Growth Factor-1 Receptor (IGF1R) Tyrosine Kinase as a Novel Cancer Therapy Approach // J. Med. Chem. 2009. V. 52. № 16. P. 4981-5004.
  17. Ning Y., Schuller A.G.P., Conover C.A., Pintar J.E. Insulin-Like Growth Factor (IGF) Binding Protein-4 Is Both a Positive and Negative Regulator of IGF Activity in Vivo // Mol. Endocrinol. 2008. V. 22. № 5. P. 1213-1225.
  18. Bach L.A.The Insulin-like Growth Factor System: Towards Clinical Applications // Clin. Biochem. Rev. 2004. V. 25. № 3. P. 155-164.
  19. Moschos S.J., Mantzoros C.S. The role of the IGF system in cancer: from basic to clinical studies and clinical applications // Oncology. 2002. V. 64. P. 317-332.
  20. Cobb L.J., Mehta H., Cohen P. Enhancing the Apoptotic Potential of Insulin-Like Growth Factor-Binding Protein-3 in Prostate Cancer by Modulation of CK2 Phosphorylation // Mol. Endocrinol. 2009. V. 23. № 10. P. 1624-1633.
  21. Roddam A.W., Allen N.E., Appleby P. et al. Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk: Analysis of Individual Patient Data from 12 Prospective Studies // Ann. Intern. Med. 2008. V. 149. № 7. P. 461-W88.
  22. Ling Y., Maile L.A., Clemmons D.R. Tyrosine phosphorylation of the ß3-subunit of the aVß3 integrin is required for membrane association of the tyrosine phosphatase SHP-2 and its further recruitment to the insulin-like growth factor I receptor // Mol. Endocrinol. 2003. V. 17. P. 1824-1833.
  23. Alberobello A.T., D'Esposito V., Marasco D. et al.Selective disruption of insulin-like growth factor-1 (IGF-1) signaling via phosphoinositide-dependent kinase-1 prevents the protective effect of IGF-1 on human cancer cell death // J. Biol. Chem. 2010. V. 285. № 9. P. 6563-6572.
  24. Werner H., Maor S.The insulin-like growth factor-I receptor gene: a downstream target for oncogene and tumor suppressor action // Trends Endocrinol. Metab. 2006. V. 17. № 6. p. 236-242.
  25. Arnold J.T., Le H., McFann K.K., Blackman M.R.Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells // Am. J. Physiol. Endocrinol. Metab. 2005. V. 288. № 3. P. 573-584.
  26. Chen C., Freeman R., Voigt L.F. et al. Prostate Cancer Risk in Relationto Selected Genetic Polymorphisms in Insulin-like Growth Factor-I, Insulin-like Growth Factor Binding Protein-3, and Insulin-like Growth Factor Receptor // Cancer Epidemiol. Biomarkers Prev. 2006. V. 15. P. 2461-2466.
  27. Chen C., Lewis S.K., Voigt L.F. et al. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein-3, and insulin // Cancer. 2004. V. 103. № 1. P. 76-84.
  28. Endogenous Hormones and Breast Cancer Collaborative Group, Key T.J., Appleby P.N., Reeves G.K., Roddam A.W. et al. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies // Lancet Oncol. 2010. V. 11. № 6. P. 530-542.
  29. Weiss J.M., Huang W.Y., Rinaldi S. et al. IGF-1 and IGFBP-3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial // Int. J. Cancer. 2007. V. 121. № 10. P. 2267-2273.
  30. Meyer F., Galan P., Douville P. et al. A prospective study of the insulin-like growth factor axis in relation with prostate cancer in the SU.VI.MAX trial // Cancer Epidemiol. Biomarkers Prev. 2005. V. 14. № 9. P. 2269-2272.
  31. Mikami K., Ozasa K., Nakao M. et al. Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: A nested case-control study in large scale cohort study in Japan // Asian Pac. J. Cancer Prev. 2009. V. 12. № 10. P. 57-61.
  32. Renehan A.G., Zwahlen M., Minder C. et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis // Lancet. 2004. V. 363. № 9418. p. 1346-1353.
  33. Reynolds A.R., Kyprianou N. Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting // Br. J. Pharmacol. 2006. V. 147 (Suppl. 2). p. 144-152.
  34. Rowlands M.-A., Gunnell D., Harris R. et al.Circulating insulin-like growth factor (IGF) peptides and prostate cancer risk: a systematic review and meta-analysis // Int. J. Cancer. 2009. V. 124. № 10. P. 2416-2429.
  35. Allen N.E., Key T.J., Appleby P.N. et al. Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition // Cancer Epidemiol. Biomarkers Prev. 2007. V. 16. № 6. P. 1121-1127.
  36. Borugian M.J., Spinelli J.J., Sun Z. et al. Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: a prospective multiethnic study // Cancer Epidemiol. Biomarkers Prev. 2008. V. 17. № 1. P. 252-254.
  37. Hong S.K., Han B.K., Jeong J.S. et al.Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men // Asian J. Androl. 2008. V. 10. № 2. P. 207-213.
  38. Neuhouser M.L., Schenk J., Song Y.-J. et al. Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein-3 and Risk of Benign Prostate Hyperplasia in the Prostate Cancer Prevention Trial // Prostate. 2008. V. 68. № 13. P. 1477-1486.
  39. Severi G., Morris H.A., MacInnis R.J. et al.Circulating Insulin-Like Growth Factor-I and Binding Protein-3 and Risk of Prostate Cancer // Cancer Epidemiol. Biomarkers Prev. 2006. V. 15. № 6. Р. 1137-1141.
  40. Fang P., Hwa V., Little B.M. et al. IGFBP-3 sensitizes prostate cancer cells to interferon-gamma-induced apoptosis // Growth Horm. IGF Res. 2008. V. 18. № 1. P. 38-46.
  41. Koike H., Ito K., Takezawa Y. et al. Insulin-like growth factor binding protein-6 inhibits prostate cancer cell proliferation: implication for anticancer effect of diethylstilbestrol in hormone refractory prostate cancer // Br. J. Cancer. 2005. V. 92. № 8. P. 1538-1544.
  42. DeGraff D.J., Aguiar A.A., Sikes R.A. Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions. // Am. J. Transl. Res. 2009. V. 1. № 2. P. 115-130.
  43. Pandini G., Mineo R., Frasca F. et al. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells // Cancer Res. 2005. V. 65. № 5. P. 1849-1857.
  44. Fan W., Yanase T., Morinaga H. et al. Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor //Biol. Chem. 2007. V. 282. № 10. P. 7329-7338.
  45. Zhu M.-L., Kyprianou N. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells // Endocr. Relat. Cancer. 2008. V. 15. № 4. P. 841-849.
  46. Camirand A., Zakikhani M., Young F. et al. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells // Breast Cancer Res. 2005. V. 7. №4. P. 570-579.
  47. Furukawa J., Wraight C.J., Freier S.M. et al.Antisense oligonucleotide targeting of insulin-like growth factor-1 receptor (IGF-1R) in prostate cancer // Prostate. 2010. V. 70. № 2. P. 206-218.
  48. Fürstenberger G., Senn E., Morant R. et al. Serum levels of IGF-1 and IGFBP-3 during adjuvant chemotherapy for primary breast cancer // Breast. 2006. V.15. № 1. P. 64-68.
  49. Lindsay C.R., Evans T.J. The insulin-like growth factor system and its receptors: A potential novel anticancer target // Biologics. 2008. V. 2. № 4. P. 855-864.
  50. Guerreiro A.S., Boller D., Doepfner K.T., Arcaro A. IGF-IR: potential role in antitumor agents // Drug. News Perspect. 2006. V. 19. № 5. P. 261-272.
  51. McKian K.P., Haluska P. Cixutumumab // Expert. Opin. Investig. Drugs. 2009. V. 18. № 7. P. 1025-1033.
  52. Kimura T., Kuwata T., Ashimine S. et al. Targeting of bone-derived insulin-like growth factor-2 by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment // Clin. Cancer Res. 2010. V. 16. № 1. P. 121-129.
  53. Dong J., Demarest S.J., Sereno A. et al. Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response // Mol. CancerTher. 2010. V. 9. № 9. P. 2593-2604.
  54. Shukla S., Gupta S. Apigenin Suppresses Insulin-like Growth Factor I Receptor Signaling in Human Prostate Cancer: An In Vitro and In Vivo Study // Mol. Carcinog. 2009. V. 48. № 3. P. 243-252.
  55. Shukla S. and Gupta S. Apigenin: a promising molecule for cancer prevention // Pharm. Res. 2010. V. 27. № 6. P. 962-978.
  56. Tang Y., Parmakhtiar B., Simoneau A.R. et al. Lycopene Enhances Docetaxel's Effect in Castration-Resistant Prostate Cancer Associated with Insulin-like Growth Factor I Receptor Levels // Neoplasia. 2011. V. 13. № 2. P. 108-119.
  57. Paz K., Hadari Y.R. Targeted therapy of the insulin-like growth factor-1 receptor in cancer // Comb. Chem. High Throughput Screen. 2008. V. 11. № 1. p. 62-69.
  58. Ulanet D.B., Ludwig D.L., Kahn C.R., Hanahan D. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy // Proc. Natl. Acad. Sci. USA. 2010. V. 107. № 24. P. 10791-10798.